{"nctId":"NCT00674739","briefTitle":"Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","startDateStruct":{"date":"2008-05"},"conditions":["Genital Warts"],"count":470,"armGroups":[{"label":"imiquimod cream","type":"EXPERIMENTAL","interventionNames":["Drug: Imiquimod"]},{"label":"3.75% imiquimod cream","type":"EXPERIMENTAL","interventionNames":["Drug: 3.75% imiquimod cream"]},{"label":"placebo cream","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo cream"]}],"interventions":[{"name":"Imiquimod","otherNames":["imiquimod 2.5% topical creram"]},{"name":"3.75% imiquimod cream","otherNames":["3.75% imiquimod topical cream"]},{"name":"placebo cream","otherNames":["placebo matching cream"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good general health\n* Diagnosis of external genital / perianal warts with at least 2 warts and no more than 30 warts\n* Negative pregnancy test (for women who are able to become pregnant)\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating or planning to become pregnant during the study\n* Evidence of clinically significant or unstable disease (such as stroke, heart attack)\n* Have any of the following conditions: HIV infection; current or history of high risk HPV infection (e.g., HPV 16, 18, etc.); outbreak of herpes genitalia in the wart areas; internal warts requiring or undergoing treatment; dermatological disease (e.g., psoriasis) or skin condition in the wart areas\n* Have received specific treatments in the treatment area(s) within the designated time period prior to study treatment initiation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Safety Variables Include Adverse Reactions (AEs), Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period.","description":"Local skin reactions in the treatment and/or immediate surrounding area were clinically identified as: erythema, edema, weeping/exudate, flaking/scaling/dryness, and erosion/ulceration. LSRs were visually assessed by investigator at each visit.\n\nRest period was a temporary interruption of dosing dur to intolerable LSRs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study","description":"Proportion of subjects with complete clearance of all warts (both presented at Baseline and newly emerged warts) at End of Study. Primary analysis performed on the Intent to Treat population with imputation (Last Observation Carried Forward)for missing data points.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.191","spread":null},{"groupId":"OG001","value":"0.272","spread":null},{"groupId":"OG002","value":"0.103","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Related Adverse Events","description":"Numbers of subjects in each treatment group reporting one or more adverse events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":178},"commonTop":["Application site pain","Application site irritation"]}}}